Weight Regain Common After Discontinuing GLP-1 Medications, Study Finds

Individuals who stop taking GLP-1 receptor agonist medications like Ozempic, Wegovy, Mounjaro, and Zepbound often regain a significant portion of the weight they lost, according to a comprehensive analysis of clinical trial data. While initial weight loss can be substantial, maintaining that loss long-term requires continued medication use and lifestyle changes.

Study Details and Findings

Researchers at the University of Cambridge, UK, analyzed 48 randomized controlled trials examining weight changes after discontinuing GLP-1 receptor agonists. Their findings, published in eClinical Medicine, revealed a distinct pattern of weight regain.

Weight increased rapidly in the initial months after stopping the medication. At 52 weeks, approximately 60% of the lost weight had been regained. The rate of weight increase then slowed, eventually plateauing around 60 weeks, with an estimated 75% of the initial weight loss being maintained in the long term. This suggests that while a complete return to pre-treatment weight is not typical, a substantial portion of the benefit is lost without continued use.

How GLP-1 Drugs Work and Why Weight Regain Occurs

GLP-1 receptor agonists, originally developed to treat type 2 diabetes, work by mimicking the effects of the naturally occurring hormone glucagon-like peptide-1 (GLP-1). WebMD explains that these drugs regulate blood sugar levels and suppress appetite, leading to increased feelings of fullness and reduced food intake.

Researchers describe the weight regain phenomenon as akin to “taking your foot off the brake.” When the medication is stopped, appetite control mechanisms are alleviated, potentially leading to increased food intake and subsequent weight gain. However, the study also suggests that changes in eating habits developed during treatment, or long-term hormonal regulation, may contribute to some weight maintenance even after discontinuation.

The Role of Lifestyle Factors

Experts emphasize that GLP-1 medications are most effective when combined with a calorie-restricted diet and regular exercise – at least 150 minutes per week. These drugs are considered an aid to appetite suppression, but long-term weight maintenance hinges on sustained lifestyle modifications.

It remains unclear whether weight regain primarily manifests as fat or muscle. Researchers caution that a significant increase in fat could negatively impact metabolic health.

Considerations for Discontinuation

Individuals considering stopping GLP-1 medication should consult with their healthcare team. A gradual reduction in dosage, combined with a strategy to stabilize food intake and activity levels, is recommended. Incorporating strength training to maintain muscle mass and basal metabolic rate is also advised.

GLP-1 Drugs and Obesity

Obesity affects over 1 billion people worldwide and increases the risk of type 2 diabetes, cardiovascular disease, and certain cancers. Weight loss can reduce these risks, but it’s crucial to have realistic expectations about the long-term effects of GLP-1 medications and to prepare for potential weight regain if treatment is discontinued.

Potential Alternatives and Supplements

As interest in medications like Ozempic and Wegovy has grown, a wave of GLP-1 branded supplements has emerged. However, experts warn that these supplements do not match the effectiveness of prescription GLP-1 agonists and are not strictly regulated. Harvard T.H. Chan School of Public Health reports that consumers cannot be certain of the ingredients or efficacy of these supplements.

the GoodRx comparison of GLP-1 drugs highlights that Ozempic (semaglutide) and Victoza (liraglutide) are used for Type 2 diabetes, while Wegovy and Saxenda are higher-dose versions for weight management.